AptaBio Therapeutics Statistics

Total Valuation

AptaBio Therapeutics has a market cap or net worth of KRW 165.59 billion. The enterprise value is 141.30 billion.

Market Cap	165.59B
Enterprise Value	141.30B

Important Dates

The next estimated earnings date is Wednesday, April 30, 2025.

Earnings Date	Apr 30, 2025
Ex-Dividend Date	n/a

Share Statistics

AptaBio Therapeutics has 26.88 million shares outstanding. The number of shares has increased by 0.84% in one year.

Current Share Class	n/a
Shares Outstanding	26.88M
Shares Change (YoY)	+0.84%
Shares Change (QoQ)	+3.41%
Owned by Insiders (%)	29.41%
Owned by Institutions (%)	3.02%
Float	18.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	47.67
PB Ratio	3.11
P/TBV Ratio	3.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.01
EV / Sales	48.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.26

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.28.

Current Ratio	2.50
Quick Ratio	2.26
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	-0.80
Interest Coverage	-5.42

Financial Efficiency

Return on equity (ROE) is -35.92% and return on invested capital (ROIC) is -17.31%.

Return on Equity (ROE)	-35.92%
Return on Assets (ROA)	-13.50%
Return on Capital (ROIC)	-17.31%
Revenue Per Employee	90.82M
Profits Per Employee	-630.31M
Employee Count	32
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-22.16%
50-Day Moving Average	7,176.20
200-Day Moving Average	7,744.05
Relative Strength Index (RSI)	40.72
Average Volume (20 Days)	74,691

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AptaBio Therapeutics had revenue of KRW 2.91 billion and -20.17 billion in losses. Loss per share was -896.77.

Revenue	2.91B
Gross Profit	226.00M
Operating Income	-19.91B
Pretax Income	-22.93B
Net Income	-20.17B
EBITDA	-19.36B
EBIT	-19.91B
Loss Per Share	-896.77

Full Income Statement

Balance Sheet

The company has 37.98 billion in cash and 13.70 billion in debt, giving a net cash position of 24.29 billion or 903.57 per share.

Cash & Cash Equivalents	37.98B
Total Debt	13.70B
Net Cash	24.29B
Net Cash Per Share	903.57
Equity (Book Value)	48.97B
Book Value Per Share	1,980.03
Working Capital	26.08B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -16.00 billion and capital expenditures -1.10 billion, giving a free cash flow of -17.10 billion.

Operating Cash Flow	-16.00B
Capital Expenditures	-1.10B
Free Cash Flow	-17.10B
FCF Per Share	-636.16

Full Cash Flow Statement

Margins

Gross Margin	7.78%
Operating Margin	-684.96%
Pretax Margin	-788.93%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

AptaBio Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.84%
Shareholder Yield	-0.84%
Earnings Yield	-14.56%
FCF Yield	-10.33%

Stock Splits

The last stock split was on August 24, 2021. It was a forward split with a ratio of 2.

Last Split Date	Aug 24, 2021
Split Type	Forward
Split Ratio	2

Scores

AptaBio Therapeutics has an Altman Z-Score of 1.06. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.06
Piotroski F-Score	n/a